← All Caribou Biosciences, INC filings

Caribou Biosciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
CRBU
Caribou Biosciences, INC
10-K: Caribou Biosciences Reports Strong Clinical Data, Faces Funding Gap
Caribou Biosciences announced promising Phase 1 clinical trial results for its CAR-T cell therapies vispa-cel and CB-011, but faces significant operating losses and requires substantial additional financing for pivotal trials.
NASDAQ
CRBU
Caribou Biosciences, INC
10-K: Caribou Biosciences Reports 2024 Financial Results, Provides Business Update
Caribou Biosciences details its 2024 financial performance and outlines key strategic advancements in its allogeneic CAR-T cell therapy programs.
NASDAQ
CRBU
Caribou Biosciences, INC
10-K: Caribou Biosciences Announces Executive Bonuses, Salary Increases, and Equity Grants
Caribou Biosciences has approved bonuses, salary increases, and equity grants for key executives, including President and CEO Rachel E. Haurwitz, Chief Financial Officer Jason V. OByrne, and Chief Legal Officer Barbara G. McClung.